Interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Journal of Medicinal Chemistry

• Publication date

  1991-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM00108A010PMID 2016705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Refined crystal structure of the triphosphate conformation of H‐ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis.

  1990cited by this paper
• Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation

  1989cited by this paper
• Three-dimensional structure of an oncogene protein: catalytic domain of human c-H-ras p21.

  1988cited by this paper
• The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product

  1988cited by this paper
• Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain.

  1988cited by this paper
• N2-phenyldeoxyguanosine: a novel selective inhibitor of herpes simplex thymidine kinase.

  1988cited by this paper
• Sugar ring conformations of guanine nucleosides by proton nuclear magnetic resonance.

  1987cited by this paper
• Molecular approaches towards an anti-ras drug.

  1987cited by this paper
• Interaction of ras oncogene product p21 with guanine nucleotides.

  1987cited by this paper
• Expression of p21 proteins in Escherichia coli and stereochemistry of the nucleotide‐binding site.

  1986cited by this paper
• The oncogenic activation of human p21ras by a novel mechanism.

  1986cited by this paper
• Ability of guanine nucleotide derivatives to bind and activate bovine transducin.

  1986cited by this paper
• Structure of the GDP domain of EF-Tu and location of the amino acids homologous to ras oncogene proteins.

  1985cited by this paper
• Synthesis and characterization of N2-(p-n-butylphenyl)-2'-deoxyguanosine and its 5'-triphosphate and their inhibition of HeLa DNA polymerase alpha.

  1984cited by this paper
• Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.

  1984cited by this paper
• ras-Related gene sequences identified and isolated from Saccharomyces cerevisiae

  1983cited by this paper
• Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses.

  1982cited by this paper
• Mechanism of activation of a human oncogene

  1982cited by this paper
• Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus

  1980cited by this paper
• A novel method for phosphorylation of nucleosides to 5'-nucleotides.

  1967cited by this paper
• Chemical synthesis of nucleoside triphosphates.

  1967cited by this paper

• Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRASG12C.

  2025cites this paper
• A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished

  2022cites this paper
• Conquering oncogenic KRAS and its bypass mechanisms

  2022cites this paper
• Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma.

  2022cites this paper
• Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.

  2022cites this paper
• NMR in integrated biophysical drug discovery for RAS: past, present, and future

  2020cites this paper
• Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades

  2020cites this paper
• KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

  2020cites this paper
• Direct inhibition of RAS: Quest for the Holy Grail?

  2019cites this paper
• Targeting the α4-α5 interface of RAS results in multiple levels of inhibition

  2019cites this paper
• Blocking Ras inhibition as an antitumor strategy.

  2018cites this paper
• Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs.

  2016cites this paper
• A Pan-GTPase Inhibitor as a Molecular Probe

  2015cites this paper
• From Unspecific Quenching to Specific Signaling: Functional GTPase Assays Utilizing Quenching Resonance Energy Transfer (QRET) Technology

  2015cites this paper
• Direct Modulation of Small GTPase Activity and Function.

  2015cites this paper
• Significance of Ras Signaling in Cancer and Strategies for its Control

  2015cites this paper
• Direkte Modulation von Aktivität und Funktion kleiner GTPasen

  2015cites this paper
• Chemical biology tools for regulating RAS signaling complexity in space and time.

  2014cites this paper
• Small-molecule modulation of Ras signaling.

  2014cites this paper
• Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population

  2012cites this paper
• GDP-capture compound--a novel tool for the profiling of GTPases in pro- and eukaryotes by capture compound mass spectrometry (CCMS).

  2010cites this paper
• Targeting the purinome.

  2009cites this paper
• H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid

  2006cites this paper
• RAS Binding Compounds

  2002cites this paper
• A NEW METHOD FOR THE SYNTHESIS OF N 2-ALKYLGUANOSINES USING MITSUNOBU REACTION AS A KEY STEP

  2001cites this paper
• SYNTHESIS OF N 2-ALKYLGUANOSINE USING MITSUNOBU REACTION AS A KEY STEP

  2001cites this paper
• Ras-A Molecular Switch Involved in Tumor Formation.

  2000cites this paper
• Ras – ein molekularer Schalter bei der Tumorentstehung

  2000cites this paper
• A Convenient Method for the Preparation of N(2)-Ethylguanine Nucleosides and Nucleotides.

  1999cites this paper
• New N-2-labelled fluorescent derivatives of guanosine nucleotides and their interaction with GTP-binding proteins

  1999cites this paper
• Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex.

  1997cites this paper
• Synthesis and evaluation of pyrazolo[3,4-b]quinoline ribofuranosides and their derivatives as inhibitors of oncogenic Ras

  1996cites this paper
• Specific and effective interaction of a guanine nucleotide analogue with small G proteins.

  1996cites this paper
• Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase.

  1996cites this paper
• Inhibition of herpes simplex virus type 1 helicase-primase by (dichloroanilino)purines and -pyrimidines.

  1995cites this paper
• Substrate and product structural requirements for binding of nucleotides to H-ras p21: the mechanism of discrimination between guanosine and adenosine nucleotides.

  1995cites this paper
• Activation of ras Oncogenes in Human Tumours

  1993cites this paper
• Quantitative structure-activity relationships of N2-phenylguanines as inhibitors of herpes simplex virus thymidine kinases.

  1992cites this paper
• p21 and other guanine-nucleotide-interacting proteins

  1991cites this paper